

27 July 2017

The Manager
Companies ASX
Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

Dear Madam

BIT225 PHASE 2 HIV-1 CLINICAL TRIAL FULLY RECRUITED

Sydney, Australia, 27 July, 2017: The Directors of Biotron Limited ('Biotron') are pleased to advise that the Phase 2 HIV-1 clinical trial (BIT225-009) of its lead antiviral drug, BIT225, is fully recruited.

The trial, which is in progress at sites Bangkok and Chiang Mai, Thailand, is a Phase 2, multi-centre, randomised, placebo-controlled, double-blind study of BIT225 and Combination Antiretroviral Therapy (approved anti-HIV-1 drugs; cART) in patients with HIV-1 infection. Patients will not have previously been on anti-HIV-1 treatment (i.e. treatment naïve) and will be commencing a cART regimen. Patients will receive cART in addition to 12 weeks with BIT225 or placebo.

As previously advised, the trial includes a dose escalation, with an initial group of 9 patients receiving 100 mg BIT225 once daily, or placebo, together with cART. A second group of 27 patients is receiving 200 mg BIT225 once daily, or placebo, together with cART. At the conclusion of the trial, patients will remain on cART as per standard treatment protocols.

The trial is designed to show a clinical benefit for BIT225 over and above that provided by cART.

All thirty six subjects have now been enrolled in the study, and are either on, or have completed, study treatment.

Biotron's Managing Director, Dr. Michelle Miller said, "We are pleased to have completed enrolment of all patients in a short time frame. Good progress is being made, and we look forward to completion of the clinical phase of the trial."

Early results from the trial are anticipated shortly after conclusion of the clinical phase, which is scheduled for October this year.

Yours sincerely



Peter J. Nightingale
Company Secretary

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for both HIV-1 and HCV and also has several earlier stage preclinical and research programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-2 9805 0488
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333

pjn9006